Hagens Berman announced a pending securities class action against Aardvark Therapeutics (AARD). The suit alleges the company made false statements about ARD-101 safety before a voluntary trial pause and FDA clinical hold. Investors who bought AARD stock between Feb. 13, 2025 and May 14, 2026 have until Oct. 13 to seek lead plaintiff status.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
